Kura Oncology's (KURA) Overweight Rating Reaffirmed at Cantor Fitzgerald

Kura Oncology (NASDAQ:KURA - Get Free Report)'s stock had its "overweight" rating reiterated by research analysts at Cantor Fitzgerald in a research report issued to clients and investors on Thursday,Benzinga reports.

A number of other brokerages have also issued reports on KURA. Barclays lowered their price target on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Wedbush reiterated an "outperform" rating and issued a $36.00 target price on shares of Kura Oncology in a report on Friday, June 20th. Mizuho cut their price target on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, May 19th. Wall Street Zen downgraded Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Finally, HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Kura Oncology in a report on Monday, April 28th. Four analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Kura Oncology has an average rating of "Moderate Buy" and an average target price of $24.50.

Kura Oncology Trading Down 1.1%

NASDAQ KURA traded down $0.07 on Thursday, hitting $5.73. 29,166 shares of the stock were exchanged, compared to its average volume of 1,233,772. The company has a debt-to-equity ratio of 0.02, a quick ratio of 8.07 and a current ratio of 8.07. Kura Oncology has a 52-week low of $5.41 and a 52-week high of $23.48. The firm has a market capitalization of $496.39 million, a P/E ratio of -2.73 and a beta of 0.40. The stock has a fifty day moving average price of $6.18 and a two-hundred day moving average price of $7.24.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The company had revenue of $14.11 million for the quarter, compared to the consensus estimate of $39.08 million. Research analysts forecast that Kura Oncology will post -2.44 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the business. State of Wyoming purchased a new stake in shares of Kura Oncology in the first quarter worth about $48,000. Virtus ETF Advisers LLC increased its holdings in Kura Oncology by 71.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock valued at $64,000 after buying an additional 3,061 shares in the last quarter. Pallas Capital Advisors LLC purchased a new stake in shares of Kura Oncology during the 1st quarter worth about $66,000. Flower City Capital acquired a new stake in shares of Kura Oncology during the 1st quarter valued at about $79,000. Finally, Magnetar Financial LLC acquired a new position in Kura Oncology in the 1st quarter worth about $79,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.